International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


Recommended Conferences for HIV AIDS Medicine

HIV AIDS Medicine

OMICS International hosted 4 national symposium on Key word HIV & AIDS Medicine.

Medicines for HIV and AIDS are used to decrease the amount of HIV in the body and to strengthen the immune system. HIV is treated using a combination of medicines to fight HIV infection. This is called antiretroviral therapy (ART). ART isn’t a cure, but it can control the virus so that you can live a longer, healthier life and reduce the risk of transmitting HIV to others. ART involves taking a combination of HIV medicines (called an HIV regimen) every day, exactly as prescribed.

OMICS International 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies  and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Medicines for HIV and AIDS are sometimes called antiretroviral medicines. HIV medicines are grouped into six drug classes according to how they fight HIV. The six drug classes are:

  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • Nucleoside reverse transcriptase inhibitors (NRTIs)
  • Protease inhibitors (PIs)
  • Fusion inhibitors
  • CCR5 antagonists (CCR5s) (also called entry inhibitors)
  • Integrase strand transfer inhibitors (INSTIs)

The six drug classes include more than 25 HIV medicines that are approved to treat HIV infection. Some HIV medicines are available in combination (in other words, two or more different HIV medicines are combined in one pill.) Although these medicines do not cure HIV, they slow the progression of HIV to AIDS. They are effective at allowing people with HIV to live their lives as normally as possible. Since the introduction of medicines to treat HIV, the death rates from AIDS have reduced dramatically. Newer medicines are more effective than medicines used in the past. If you have HIV and do not take HIV medicines, eventually - typically, over a number of years - your viral load increases and the number of CD4 T cells decreases significantly. Your immune system becomes very weak. This means that you are open to getting infections and your body is unable to fight the infection. These infections can become serious and overwhelming for your body and you are likely to die. These medicines do no cure people the infection is still there in the body. They can still spread HIV to others through unprotected sex and needle sharing. According to the recent research in the field of medicine the first complete treatment for AIDS that is taken once a day as a single pill is expected to be available soon. The new drug is a combination of drugs already on the market — Sustiva, by Bristol-Myers Squibb, and Truvada, by Gilead Sciences. HIV statistics for the end of 2011 indicate that around 34 million people are living with HIV. Each year around 2.5 million more people become infected with HIV and 1.7 million die of AIDS. Although HIV and AIDS are found in all parts of the world, some areas are more afflicted than others. The U.S. Department of Health and Human Services (HHS) provides guidelines on the use of HIV medicines to treat HIV infection. The HHS guidelines recommend starting ART with a regimen of three HIV medicines from at least two different drug classes. NIH AIDS Info’s FDA-Approved Medicines provides a complete list of HIV medicines, grouped by class, that are approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in the United States.

It has been estimated that between US$22-24 billion will be needed annually by 2015, in order to reach global targets. In 2011, there was a total global investment of 16.8 billion, a gap in resources of 30 percent. The Global Fund, which provides antiretroviral treatment to 2.5 million people worldwide, received $11.3 billion for three years in 2010 out of the $20 billion it calculated it needed over this period. Funding from the US government, mainly through PEPFAR, was also flat-lined from 2009-2010 for the first time since its creation in 2003. That year the PEPFAR budget for antiretroviral treatment was also reduced and funds for ARV drugs fell by 17 percent. The percentage of countries where antiretroviral treatment programmes were adversely affected by reduced external funding rose from 11 percent to 21 percent from July 2008 to July 2009. International funding still deteriorated in 2011 - the improvement in global available resources was largely a result of many countries increasing their domestic investment in HIV and AIDS. Domestic spending in low- and middle-income countries increased from US$ 3.9 billion in 2005 to nearly $8.6 billion in 2011, and for the first time, that year domestic resources outnumbered international resources in the HIV response. Eastern Europe and Central Asia are seen as particularly vulnerable to the effects of reduced external funding and the economic crisis. Already less than a quarter of people in need of treatment in the region are receiving it but drug stock-outs are common and government health expenditure on HIV and AIDS treatment programmes has fallen sharply, according to UNAIDS country coordinators. In September 2010, the arrests of activists in Moscow protesting against ARV drug stock outs in hospitals highlighted the grave lack of access to HIV treatment in Russia.

Relevant conferences

  1. 4th HIV/AIDS, STDs, & STIs Conference,                                                    November 30-December 02, 2015 Hilton Atlanta Airport, Atlanta, USA
  2. 4th Immunology Conference, September 28-30, 2015 Houston, Texas, USA
  3. 2nd Infectious Diseases Conference, August 25-27, 2016 Philadelphia, USA
  4. 2nd Influenza Conference, September 12-14, 2016 Berlin, Germany
  5. Infection Prevention and Control Conference, Aug 1-2, 2016 Frankfurt, Germany
  6. 2nd Innate Immunity Conference, July 21-22, 2016 Berlin, Germany
  7. 2nd Parasitology Conference, August 01-03, 2016 Manchester, UK
  8. 2nd Antibodies Conference, July 14-15, 2016 Philadelphia, USA
  9. 2nd Neuroimmunology & Therapeutics Conference,                                        March 31-April 02, 2016 Atlanta, USA
  10.  7th Vaccines & Vaccination Conference, September 28-30, 2015 Dubai, UAE
  11. 9th Vaccines & Vaccination Conference,                                                           November 30-December 02, 2015 San Francisco, USA
  12. 10th Vaccines & Vaccination Conference, June 16-18, 2016 Rome, Italy
  13. 13th Vaccines & Vaccination Conference,                                                         November 10-12, 2016 Melbourne, Australia
  14. 2nd Applied Microbiology Conference,                                                             October 31-November 02, 2016 Istanbul, Turkey
  15. 6th Cell & Stem Cells Research Conference,                                                      February 29-March 02, 2016 Philadelphia, USA
  16.  2nd Antibiotics Conference October 03-05, 2016 London, UK
  17. 5th Cancer Therapy Conference, September 28-30, 2015 Atlanta, Georgia, USA
  18. Beneficial Microbes: Food, Pharma, Aqua & Beverages Industry Conference, September 23-25, 2016 Phoenix, USA
  19. 4th Bacteriology and Infectious Diseases Conference,                                        May 16-18, 2016 San Antonio, USA
  20. Allergy Conference, March 29-30, 2016 Valencia, Spain
  21. United States Conference on AIDS
  22. 2015 National HIV Prevention Conference
  23. The North American Housing and HIV/AIDS Research Summit VIII
  24. World STI & HIV Congress joint with the Australasian HIV & AIDS Conference
  25. 15th European AIDS Conference
  26. 7th International Workshop on HIV Persistence during Therapy
  27. World STI & HIV Congress
  28. 17th Bangkok International Symposium on HIV Medicine
  29. World STI & HIV Congress
  30. 7th International Workshop on HIV Persistence, Reservoirs and Cure
  31. 27th Annual National Conference on Social Work and HIV/AIDS
  32. 21st International AIDS Conference

Relevant Societies

  1. Global Fund to Fight AIDS
  2. Tuberculosis and Malaria
  3. International Aids Society
  4. UNAIDS, International Association of Providers of AIDS Care (IAPAC)
  5. The HIV Medicine Association (HIVMA)
  6. Global Strategies for HIV Prevention
  7. The Foundation for AIDS Research
  8. The International AIDS Vaccine Initiative
  9. The Elizabeth Glaser Pediatric AIDS Foundation
  10. The Forum for Collaborative HIV Research
  11. The Elton John AIDS Foundation

Relevant Companies

  1. Bristol-Myers Squibb
  2. Pfizer
  3. GlaxoSmithKline plc.
  4. Gilead
  5. Astellas
  6. Bayer's Pharma
  7. Cipla
  8. Merck & Co.
  9. Natco Pharma
  10. Novartis
  11. Novo Nordisk
  12. Roche
  13. Sunpharma
  14. Sanofi


This page will be updated regularly.

This page was last updated on December 6, 2021

Conference Series LLC LTD Destinations